ABSTRACT
Co-infection with two SARS-CoV-2 variants is rarely detected, but may have clinical implications and is hypothesized to be a precursor to SARS-CoV-2 variant recombination. It is therefore important to rapidly identify co-infection cases. Here, we report two cases of co-infection detected during routine genomic surveillance. Both samples were initially suspected to have been cross-contaminated due to the unusual number of private mutations identified by Nextclade and positions flagged for nucleotide mixtures by Bammix. To rule out cross-contamination, we decontaminated the workspaces and resequenced the samples. However, the anomalies remained and the samples were therefore investigated for co-infection. To validate this hypothesis, we created a bioinformatics pipeline to determine the lineages present in the samples, performed de novo assembly, and investigated the alternative allele fraction of mutations mapping to both variants. Freyja was used and showed an estimated lineage abundance of 49.81% and 48.09% for Delta and Omicron, respectively, in the first sample. For the second sample, Delta had 82.76% abundance and Omicron had 4.99% abundance, with the presence of 12.24% abundance for other variants. Our findings support that the first sample is a case of co-infection of Delta and Omicron variants while the second sample is a cryptic co-infection of both variants, potentially undergoing recombination events. This study highlights the importance of developing a more stringent bioinformatics workflow to identify co-infection cases in genomic surveillance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work was supported by the UK Research and Innovation Global effort on COVID-19 (MR/V035444/1) and Wellcome (207569/Z/17/Z, 224520/Z/21/Z). J.H. is funded by the Medical Research Council (MC_UU_12014/12) and KB is supported by a Medical Research Council New Investigator Research Grant (MR/X002047/1) and a University of Glasgow Lord Kelvin/Adam Smith Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Institute for Tropical Medicine Institutional Review Board granted ethical approval for this work under IRB Assigned Number 2020-38, titled 'Implementing Genomic Surveillance to Support SARS-CoV-2 Control and Mitigation Strategies in the Philippines'. As part of genomic surveillance protocol, all genome sequences are made publicly available on the EpiCoV database of the Global Initiative for Sharing All Influenza Data (GISAID).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The samples are available in bioproject PRJNA1124409 on Sequence Read Archive. The FASTA files and metadata are also available in GISAID as compiled EPI SET (EPI_SET_240625us).
All sequences processed for Philippine SARS-CoV-2 genomic surveillance, including those used in this study, have been uploaded to and are publicly available on the EpiCoV database of the Global Initiative for Sharing All Influenza Data (GISAID). Batches containing the flagged samples analyzed in this study are accessible in GISAID under the compiled EPI SET (EPI_SET_240703bc), as detailed in Supplementary Table 1, and in Bioproject PRJNA1124409 on the Sequence Read Archive (SRA).
